ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 1030 • 2014 ACR/ARHP Annual Meeting

    ABT-122, a Novel Dual Variable Domain (DVD)-IgTM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects

    Melanie Ruzek1, Donna Conlon1, Heikki Mansikka2, Robert Padley2 and Carolyn Cuff3, 1AbbVie, Inc, Worcester, MA, 2AbbVie, Inc, North Chicago, IL, 3Immunology, AbbVie, Inc, Worcester, MA

    Background/Purpose: TNF and IL-17 contribute to the pathogenesis of several inflammatory disorders and are known to synergistically induce chemokines and cytokines, including chemokine (C-X-C motif)…
  • Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting

    β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10

    Georg Pongratz1, Clemens Wiest2, Madlen Melzer2 and Rainer Straub3, 1Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, 2University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
  • Abstract Number: 951 • 2014 ACR/ARHP Annual Meeting

    Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects

    Heikki Mansikka1, Melanie Ruzek2, Margaret Hugunin2, Alexander Ivanov2, Alyssa Brito2, Anca Clabbers2, Carolyn Cuff3, Chung-Ming Hsieh2, Martin Okun1, Renee Heuser1, David Carter1, Barbara Hendrickson1, Dipak Pisal1, Sandra Goss1, Jia Liu1, Charles Locke1, Nasser Khan1 and Robert Padley1, 1AbbVie, Inc, North Chicago, IL, 2AbbVie, Inc, Worcester, MA, 3Immunology, AbbVie, Inc, Worcester, MA

    Background/Purpose: Several lines of evidence indicate that greater clinical efficacy and protection of joints may be possible in patients with RA by neutralizing TNF and…
  • Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting

    Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…
  • Abstract Number: 947 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of NNC0114­0006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis

    Juan D. Cañete1, Piotr Leszczynski2, Rikke Riisbro3 and Klaus S. Frederiksen3, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, 3Novo Nordisk A/S, Søborg, Denmark

    Background/Purpose A phase 2, randomised, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of NNC0114-0006 in patients with active rheumatoid arthritis…
  • Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh1, Sharayah Riegsecker2, Sadiq Umar1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 2Department of Pharmacology, University of Toledo, Toledo, OH

    Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
  • Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

    Jing He1, Xia Zhang2, Xiaolin Sun3, Jianping Guo3, Yunbo Wei4, Zhaohua Hou4, Yu Di5 and Zhanguo Li3, 1Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 4Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, 5Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria

    Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
  • Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting

    Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE

    Jens Y. Humrich1, Caroline von Spee-Mayer1, Elise Siegert1, Angelika Rose1, Tobias Alexander2, Falk Hiepe1, Andreas Radbruch3, Gerd Burmester4 and Gabriela Riemekasten1, 1Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 4Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting

    Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis

    Anderson Gaweco1,2, Samantha Palmer1, Rambon Shamilov1, Caroline Stremnitzer1, Katie Matthews1, Michael Fisher1, William Windsor1, James Blinn1, Ellen M. Ginzler3 and Jefferson Tilley1, 1Innovimmune Biotherapeutics, Brooklyn, NY, 2SUNY-Downstate Medical Center, Brooklyn, NY, 3Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY

    Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
  • Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting

    Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
  • Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting

    Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome

    Loredana Cifaldi1, Giusi Prencipe2, Ivan Caiello2, Claudia Bracaglia2, Raffaele Strippoli3 and Fabrizio De Benedetti Sr.2, 1Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy

    Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
  • Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting

    COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic

    Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
  • Abstract Number: 1168 • 2013 ACR/ARHP Annual Meeting

    Innate Immune Cell Production Of Interleukin-12 Drives CpG-Induced Macrophage Activation Syndrome

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatrics/Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Hemophagocytic syndromes are caused by an uncontrolled systemic inflammatory response resulting in cytopenias, multisystem organ failure, and rapid death, often despite aggressive therapy. Macrophage…
  • Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting

    The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF

    Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland

    Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
  • Abstract Number: 939 • 2013 ACR/ARHP Annual Meeting

    Reduction Of Circulating Blood Neutrophils In Mice By Anti-IL-6R Alpha Monoclonal Antibody is Not Due To Apoptosis Or Blockade Of Neutrophil Differentiation

    Ludmila Kelly, Vilma Decman and Dimitris Skokos, Research, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

    Background/Purpose: Blockade of IL-6/IL-6Rα signaling is associated with a reduction of circulating neutrophils in the blood of patients treated with anti-IL-6Rα mAb but the mechanism…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences